Boston Scientific Co. (NYSE:BSX) Shares Acquired by Castle Hook Partners LP

Castle Hook Partners LP grew its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 146.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 762,073 shares of the medical equipment provider's stock after buying an additional 453,374 shares during the period. Boston Scientific makes up about 0.8% of Castle Hook Partners LP's holdings, making the stock its 24th biggest holding. Castle Hook Partners LP owned 0.05% of Boston Scientific worth $68,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Parnassus Investments LLC increased its position in Boston Scientific by 0.7% during the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after acquiring an additional 97 shares during the last quarter. Baldwin Investment Management LLC grew its stake in shares of Boston Scientific by 1.2% during the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after purchasing an additional 102 shares during the period. Evergreen Capital Management LLC increased its position in shares of Boston Scientific by 1.7% during the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after purchasing an additional 106 shares during the last quarter. PDS Planning Inc lifted its stake in shares of Boston Scientific by 1.5% in the 4th quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after purchasing an additional 113 shares during the period. Finally, Adero Partners LLC boosted its holdings in shares of Boston Scientific by 3.3% in the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after buying an additional 120 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 12,000 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the sale, the director now owns 24,398 shares of the company's stock, valued at $2,573,501.04. This trade represents a 32.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the sale, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This trade represents a 9.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 300,497 shares of company stock worth $31,056,815 over the last three months. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 0.4 %

NYSE BSX traded down $0.42 during midday trading on Friday, hitting $102.87. 3,609,449 shares of the company traded hands, compared to its average volume of 6,332,865. The company has a market cap of $152.19 billion, a PE ratio of 82.30, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17. The company's 50-day simple moving average is $98.68 and its 200-day simple moving average is $95.93.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the previous year, the company posted $0.56 earnings per share. The firm's revenue was up 20.9% on a year-over-year basis. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on BSX shares. Stifel Nicolaus raised their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Argus set a $130.00 price objective on shares of Boston Scientific in a report on Tuesday, February 18th. StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a report on Thursday. Twenty-three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $114.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.